Investigational drug · Phase 3
ALN-CIDEB
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "ALN-CIDEB"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALN-CIDEB", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis
- MASLD
- Alcohol-Associated Liver Disease
- ALD
- MASH
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ALN-CIDEB" as an intervention, largest first.
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07631637 · 360 participants (planned) · Start Jul 6, 2026 · Primary completion Jan 29, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; MASH
Sites: Tucson, Arizona; Pasadena, California; Rialto, California · 24 sites in all
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Pivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07933328 · 120 participants (planned) · Start Dec 9, 2026 · Primary completion May 7, 2029
Drug: ALN-CIDEB; Placebo · For: Alcohol-Associated Liver Disease; ALD
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06836609 · 118 participants · Start Apr 28, 2025 · Primary completion Aug 17, 2027
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Tucson, Arizona; London, United Kingdom · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metabolic Dysfunction-Associated Steatotic Liver Disease
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.